Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship

Recently, small-molecule compounds have been reported to block the PD-1/PD-L1 interaction by inducing the dimerization of PD-L1. All these inhibitors had a common scaffold and interacted with the cavity formed by two PD-L1 monomers. This special interactive mode provided clues for the structure-based drug design, however, also showed limitations for the discovery of small-molecule inhibitors with new scaffolds. In this study, we revealed the structure-activity relationship of the current small-molecule inhibitors targeting dimerization of PD-L1 by predicting their binding and unbinding mechanism via conventional molecular dynamics and metadynamics simulation. During the binding process, the representative inhibitors (BMS-8 and BMS-1166) tended to have a more stable binding mode with one PD-L1 monomer than the other and the small-molecule inducing PD-L1 dimerization was further stabilized by the non-polar interaction of Ile54, Tyr56, Met115, Ala121, and Tyr123 on both monomers and the water bridges involved in ALys124. The unbinding process prediction showed that the PD-L1 dimerization kept stable upon the dissociation of ligands. It's indicated that the formation and stability of the small-molecule inducing PD-L1 dimerization was the key factor for the inhibitory activities of these ligands. The contact analysis, R-group based quantitative structure-activity relationship (QSAR) analysis and molecular docking further suggested that each attachment point on the core scaffold of ligands had a specific preference for pharmacophore elements when improving the inhibitory activities by structural modifications. Taken together, the results in this study could guide the structural optimization and the further discovery of novel small-molecule inhibitors targeting PD-L1.

[1]  Laxmikant V. Kale,et al.  NAMD2: Greater Scalability for Parallel Molecular Dynamics , 1999 .

[2]  Peter Gedeck,et al.  Calculation of Intersubstituent Similarity Using R-Group Descriptors , 2003, J. Chem. Inf. Comput. Sci..

[3]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[4]  Peter Gedeck,et al.  Use of the R-group descriptor for alignment-free QSAR , 2005 .

[5]  Massimiliano Bonomi,et al.  PLUMED: A portable plugin for free-energy calculations with molecular dynamics , 2009, Comput. Phys. Commun..

[6]  Francesco Luigi Gervasio,et al.  Exploring complex protein-ligand recognition mechanisms with coarse metadynamics. , 2009, The journal of physical chemistry. B.

[7]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[8]  Woody Sherman,et al.  Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods , 2010, J. Cheminformatics.

[9]  Massimiliano Bonomi,et al.  Metadynamics , 2019, ioChem-BD Computational Chemistry Datasets.

[10]  Xiaojie Jin,et al.  Exploring the Molecular Mechanism of Cross-Resistance to HIV-1 Integrase Strand Transfer Inhibitors by Molecular Dynamics Simulation and Residue Interaction Network Analysis , 2013, J. Chem. Inf. Model..

[11]  Diego F. Gauto,et al.  Solvent structure improves docking prediction in lectin-carbohydrate complexes. , 2013, Glycobiology.

[12]  A. Ghazalpour,et al.  Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[13]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[14]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[15]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[16]  A. Cavalli,et al.  Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms. , 2015, Accounts of chemical research.

[17]  A. Abdel-Magid.  Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections. , 2015, ACS medicinal chemistry letters.

[18]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[19]  Lei Liu,et al.  Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. , 2015, Angewandte Chemie.

[20]  K. Zak,et al.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. , 2015, Structure.

[21]  Nilanjan Adhikari,et al.  Structural findings of phenylindoles as cytotoxic antimitotic agents in human breast cancer cell lines through multiple validated QSAR studies. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[22]  Rafael C. Bernardi,et al.  Enhanced sampling techniques in molecular dynamics simulations of biological systems. , 2015, Biochimica et biophysica acta.

[23]  Jun-hai Xiao,et al.  Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  K. Zak,et al.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.

[25]  Richard H. Henchman,et al.  Water Determines the Structure and Dynamics of Proteins. , 2016, Chemical reviews.

[26]  G. Gao,et al.  Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies , 2016, Protein & Cell.

[27]  S. Ryu,et al.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy , 2016, Nature Communications.

[28]  G. Rabinovich,et al.  Impact of human galectin-1 binding to saccharide ligands on dimer dissociation kinetics and structure. , 2016, Glycobiology.

[29]  K. Zak,et al.  Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015) , 2016, Expert opinion on therapeutic patents.

[30]  A. Kruse,et al.  Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. , 2016, Structure.

[31]  Ju Yeon Lee,et al.  Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab , 2017, Scientific Reports.

[32]  G. Gao,et al.  Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy , 2016, Cell Research.

[33]  Aiwu Zhou,et al.  Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade , 2017, Cell Discovery.

[34]  Youyong Li,et al.  Characterizing Drug-Target Residence Time with Metadynamics: How To Achieve Dissociation Rate Efficiently without Losing Accuracy against Time-Consuming Approaches , 2017, J. Chem. Inf. Model..

[35]  M. Parrinello,et al.  Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations. , 2017, Journal of the American Chemical Society.

[36]  G. Gao,et al.  Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab , 2017, Protein & Cell.

[37]  T. Holak,et al.  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. , 2017, Journal of medicinal chemistry.

[38]  Jiawei Wu,et al.  Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab , 2017, Oncotarget.

[39]  L. Skalniak,et al.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. , 2017, Angewandte Chemie.

[40]  L. Skalniak,et al.  Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells , 2017, Oncotarget.

[41]  Tingjun Hou,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. , 2018, Physical chemistry chemical physics : PCCP.

[42]  G. Kocic,et al.  Benzimidazoles as novel deoxyribonuclease I inhibitors , 2018, Journal of cellular biochemistry.

[43]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 8. Predicting binding free energies and poses of protein–RNA complexes , 2018, RNA.

[44]  G. Kocic,et al.  Synthesis and DNase I inhibitory properties of some 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines. , 2018, Bioorganic chemistry.

[45]  H. Xie,et al.  Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. , 2019, Journal of medicinal chemistry.

[46]  E. Olejniczak,et al.  Fragment-based screening of programmed death ligand 1 (PD-L1). , 2019, Bioorganic & medicinal chemistry letters.